Skip to main content
Download PDF
  • Published:

Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case report

Biological Procedures Online volume 6, pages 144–148 (2004)Cite this article

Abstract

Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance. Detection of mutations is helpful in clinical management of imatinib resistance. We established a very sensitive (ASO) PCR to detect mutations in an imatinib-resistant CML patient. Mutations C944T and T1052C were detected which cause complete partial imatinib resistance, respectively. This is the first report of multiple point mutations conferring primary imatinib resistance in same patient at the same time. Understanding the biological reasons of primary imatinib resistance is one of the emerging issues of pharmacogenomics and will be helpful in understanding primary resistance of molecularly-targeted cancer therapies. It will also be of great utilization in clinical management of imatinib resistance. Moreover, this ASO-PCR assay is very effective in detecting mutations related to imatinib resistance.

References

  1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003; 349(15):1451–1464.

    Article  PubMed  CAS  Google Scholar 

  2. Steensma DP. The chronic myeloproliferative disorders: an historical perspective. Curr Hematol Rep 2003; 2(3):221–230.

    PubMed  Google Scholar 

  3. Kantarjian H, O’Brien S, Cortes J et al. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer 2003; 98(1):81–85.

    Article  PubMed  Google Scholar 

  4. Cortes J, Talpaz M, O’Brien S et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 98(6):1105–1113.

    Article  PubMed  CAS  Google Scholar 

  5. Kantarjian H, O’Brien S, Cortes J et al. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer 2003; 98(7):1430–1437.

    Article  PubMed  CAS  Google Scholar 

  6. Sattler M, Scheijen B, Weisberg E, Griffin JD. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol 2003; 532:121–140.

    PubMed  CAS  Google Scholar 

  7. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973–1998). Cancer 2003; 97(9):2229–2235. Erratum in: Cancer 1993; 98(3):659.

    Article  PubMed  Google Scholar 

  8. Kuhr T, Burgstaller S, Apfelbeck U et al. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic phase chronic myeloid leukemia (CML). Leuk Res 2003; 27(5):405–411.

    Article  PubMed  CAS  Google Scholar 

  9. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003; 55(3):401–423.

    Article  PubMed  CAS  Google Scholar 

  10. Fujii T, Inoue S, Karashima T et al. Real-time PCR quantification of bcr/abl chimera and WT1 genes in chronic myeloid leukemia. Rinsho Byori 2003; 51(9):839–846.

    PubMed  CAS  Google Scholar 

  11. Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003; 40(2 Suppl 3):69–79.

    PubMed  CAS  Google Scholar 

  12. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI -571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293(5531):876–880.

    Article  PubMed  CAS  Google Scholar 

  13. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2(2):117–125.

    Article  PubMed  CAS  Google Scholar 

  14. Liu WH, Makrigiorgos GM. Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571. Leuk Res 2003; 27(11):979–982.

    Article  PubMed  CAS  Google Scholar 

  15. von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003; 17(5):829–838.

    Article  CAS  Google Scholar 

  16. Branford S, Rudzki Z, Walsh S et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P -loop) are associated with a poor prognosis. Blood 2003; 102(1):276–283.

    Article  PubMed  CAS  Google Scholar 

  17. Roumiantsev S, Shah NP, Gorre ME et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002; 99(16):10700–10705.

    Article  PubMed  CAS  Google Scholar 

  18. Roche-Lestienne C, Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol 2003; 40(2 Suppl 3):80–82.

    PubMed  CAS  Google Scholar 

  19. Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 2003; 40(1):50–58.

    Article  PubMed  CAS  Google Scholar 

  20. La Rosee P, Johnson K, O’Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002; 30(7):729–737.

    Article  PubMed  Google Scholar 

  21. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100(3):1014–1018.

    Article  PubMed  CAS  Google Scholar 

  22. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989: E.3-E.4.

    Google Scholar 

  23. Sillaber C, Mayerhofer M, Agis H, Sagaster V et al. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr 2003; 115(13–14):485–504.

    Article  PubMed  CAS  Google Scholar 

  24. Steegmann JL, Moreno G, Alaez C et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003; 88(7):762–768.

    PubMed  CAS  Google Scholar 

  25. Garside R, Round A, Dalzell K et al. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review. Health Technol Assess 2002; 6(33):1–162.

    PubMed  CAS  Google Scholar 

  26. O’Dwyer ME, Mauro MJ, Druker BJ. STI571 as a targeted therapy for CML. Cancer Invest 2003; 21(3):429–438.

    Article  PubMed  CAS  Google Scholar 

  27. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112(6):831–843.

    Article  PubMed  CAS  Google Scholar 

  28. Gambacorti-Passerini C, Piazza R, D’Incalci M. Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. Blood 2003; 102(5):1933–1934.

    Article  PubMed  CAS  Google Scholar 

  29. Bugert P, Lese A, Meckies J, Zieger W, Eichler H, Kluter H. Optimized sensitivity of allele-specific PCR for prenatal typing of human platelet alloantigen single nucleotide polymorphisms. Biotechniques 2003; 35(1):170–174.

    PubMed  CAS  Google Scholar 

  30. Gerstner A, DeFord JH, Papaconstantinou J. Comparison of two PCR-based methods and automated DNA sequencing for prop-1 genotyping in Ames dwarf mice. Mutat Res 2003; 528(1–2):37–44.

    PubMed  CAS  Google Scholar 

  31. Latorra D, Campbell K, Wolter A, Hurley JM. Enhanced allele-specific PCR discrimination in SNP genotyping using 3’ locked nucleic acid (LNA) primers. Hum Mutat 2003; 22(1):79–85.

    Article  PubMed  CAS  Google Scholar 

  32. Kantarjian HM, Talpaz M, O’Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101(2):473–475.

    Article  PubMed  CAS  Google Scholar 

  33. McCann SR, Gately K, Conneally E et al. Molecular response to imatinib mesylate following relapse after allogenic SCT for CML. Blood 2003; 101(3):1200–1201.

    Article  PubMed  CAS  Google Scholar 

  34. Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 2003; 40(1):50–58.

    Article  PubMed  CAS  Google Scholar 

  35. La Rosee P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl positive cell lines. Blood 2004; 103(1):208–215.

    Article  PubMed  CAS  Google Scholar 

  36. O’Brien S, Giles F, Talpaz M et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003; 98(5):888–893.

    Article  PubMed  CAS  Google Scholar 

  37. Yee KW, Keating A. Advances in targeted therapy for chronic myeloid leukemia. Expert Rev Anticancer Ther 2003; 3(3):295–310.

    Article  PubMed  CAS  Google Scholar 

  38. Frankel SR. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom’s macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol 2003; 30(2):300–304.

    Article  PubMed  CAS  Google Scholar 

  39. Corbin AS, Rosee PL, Stoffregen EP et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101(11):4611–4614.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Molecular Cytogenetics & Oncology Research Lab., National Institute for Biotechnology & Genetic Engineering (NIBGE), Jhang Road, 38000, Faisalabad, Pakistan

    Zafar Iqbal (Scientific Officer), Rubina T. Siddiqui & Javed A. Qureshi

Authors
  1. Zafar Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rubina T. Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javed A. Qureshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zafar Iqbal.

Additional information

Published: July 1, 2004.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iqbal, Z., Siddiqui, R.T. & Qureshi, J.A. Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case report. Biol. Proced. Online 6, 144–148 (2004). https://doi.org/10.1251/bpo83

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1251/bpo83

Indexing terms

Biological Procedures Online

ISSN: 1480-9222

Contact us